CA2840030A1 - Novel compounds for the treatment of inflammatory bowel disease - Google Patents

Novel compounds for the treatment of inflammatory bowel disease Download PDF

Info

Publication number
CA2840030A1
CA2840030A1 CA2840030A CA2840030A CA2840030A1 CA 2840030 A1 CA2840030 A1 CA 2840030A1 CA 2840030 A CA2840030 A CA 2840030A CA 2840030 A CA2840030 A CA 2840030A CA 2840030 A1 CA2840030 A1 CA 2840030A1
Authority
CA
Canada
Prior art keywords
mir
nucleic acid
sequence
acid molecule
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2840030A
Other languages
English (en)
French (fr)
Inventor
Alexander Schmidt
Katharina VELTMAN
Christoph CICHON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Münster
Original Assignee
University of Münster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Münster filed Critical University of Münster
Publication of CA2840030A1 publication Critical patent/CA2840030A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2840030A 2011-08-12 2012-08-09 Novel compounds for the treatment of inflammatory bowel disease Abandoned CA2840030A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11006650 2011-08-12
EP11006650.3 2011-08-12
EP11185604.3 2011-10-18
EP11185604 2011-10-18
PCT/EP2012/065568 WO2013023982A1 (en) 2011-08-12 2012-08-09 Novel compounds for the treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
CA2840030A1 true CA2840030A1 (en) 2013-02-21

Family

ID=46826440

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2840030A Abandoned CA2840030A1 (en) 2011-08-12 2012-08-09 Novel compounds for the treatment of inflammatory bowel disease

Country Status (6)

Country Link
US (1) US20140199402A1 (enExample)
EP (1) EP2742137A1 (enExample)
JP (1) JP2014525749A (enExample)
AU (1) AU2012296977A1 (enExample)
CA (1) CA2840030A1 (enExample)
WO (1) WO2013023982A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9683263B2 (en) * 2013-05-20 2017-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection and treatment of irritable bowel syndrome
EP3060649A4 (en) * 2013-10-23 2017-07-12 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Reprogramming cardiomyocytes with one transcription factor
KR102733066B1 (ko) 2015-06-26 2024-11-21 주식회사 파마리서치 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물
WO2016208880A1 (ko) * 2015-06-26 2016-12-29 주식회사 파마리서치프로덕트 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물
EP3969019A4 (en) * 2019-05-14 2023-06-07 Hadasit Medical Research Services and Development Ltd. MILK-DERIVED EXTRACELLULAR VESICLES FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
ES2534300T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US9006191B2 (en) * 2007-12-27 2015-04-14 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering RNA
WO2009120877A2 (en) * 2008-03-26 2009-10-01 The Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
WO2010034479A1 (en) * 2008-09-23 2010-04-01 Eth Zurich Protective e. coli strains for reducing the salmonella typhimurium pathogen load in the intestines

Also Published As

Publication number Publication date
WO2013023982A1 (en) 2013-02-21
EP2742137A1 (en) 2014-06-18
AU2012296977A1 (en) 2014-01-23
US20140199402A1 (en) 2014-07-17
JP2014525749A (ja) 2014-10-02

Similar Documents

Publication Publication Date Title
del Pozo‐Acebo et al. Eating microRNAs: pharmacological opportunities for cross‐kingdom regulation and implications in host gene and gut microbiota modulation
Mizuno et al. Exopolysaccharides from Streptococcus thermophilus ST538 modulate the antiviral innate immune response in porcine intestinal epitheliocytes
Yu et al. Fermentation results in quantitative changes in milk-derived exosomes and different effects on cell growth and survival
EP2344626B1 (en) Reduced colonization of microbes at the mucosa
Chen et al. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications
Guzman et al. Diet, microbiome, and the intestinal epithelium: an essential triumvirate?
CN103930117B (zh) 用作用于营养和医药应用的益生菌剂的细菌
Duell et al. Epithelial cell coculture models for studying infectious diseases: benefits and limitations
EP2455486B1 (en) Method for screening for diet providing production of milk having immunoregulatory action
Zhu et al. Inulin fermentation by lactobacilli and bifidobacteria from dairy calves
US20140199402A1 (en) Novel compounds for the treatment of inflammatory bowel disease
JP5099649B2 (ja) 乳酸菌由来の２本鎖ｒｎａ
Taibi et al. Time‐and strain‐specific downregulation of intestinal EPAS1 via miR‐148a by Bifidobacterium bifidum
JP2026083226A (ja) マイクロバイオーム調節のための組成物及び方法
US20110245325A1 (en) Pharmaceutical composition for treatment of cancer and asthma
Bailey et al. Identification and characterisation of an iron-responsive candidate probiotic
CN112972702A (zh) 用于治疗耐药菌感染的外泌体制剂
KR20210039495A (ko) 피드백이 가능한 합성 유전자, 표적 시드 매치 카세트, 및 그 용도
CN104099279A (zh) 一种缓解畜禽应激的复合微生态制剂及应用
CN110049770A (zh) 肌肉分化诱导剂
Khokhlova et al. Heterologous expression of secreted biologically active human interleukin-10 in Bifidobacterium breve
JP2023033337A (ja) 糖吸収促進用組成物
Ren et al. Relationship between pathogenic E. coli O78-induced intestinal epithelial barrier damage and Zonulin expression levels in yaks
Albarracin et al. Exopolysaccharides From Streptococcus thermophilus ST538
LeBegue The Pharmabiotic for Phenylketonuria: Development of a Novel Therapeutic

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180809